Cardiovascular hazard and non-steroidal anti-inflammatory drugs
about
sameAs
Biomarker-based drug safety assessment in the age of systems pharmacology: from foundational to regulatory scienceReciprocal crosstalk between dendritic cells and natural killer cells under the effects of PGE2 in immunity and immunopathologyDynamic simulations on the arachidonic acid metabolic networkInternalization and recycling of the human prostacyclin receptor is modulated through its isoprenylation-dependent interaction with the delta subunit of cGMP phosphodiesterase 6.Clinical pharmacology of etoricoxib.Systems pharmacology dissection of the anti-inflammatory mechanism for the medicinal herb Folium eriobotryae.Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory painLarge-scale prediction and testing of drug activity on side-effect targets.Priorities and standards in pharmacogenetic research.New families of bioactive oxidized phospholipids generated by immune cells: identification and signaling actions.Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics.Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs.Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders.Effects of EP1 receptor on cerebral blood flow in the middle cerebral artery occlusion model of stroke in mice.Nonselective nonsteroidal antiinflammatory drugs and cardiovascular risk: are they safe?Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK functionFinding multiple target optimal intervention in disease-related molecular network.Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence.Commonality of defensive roles of COX-2 in the lung and gutIdentification and Characterization of Novel Microsomal Prostaglandin E Synthase-1 Inhibitors for Analgesia.Oxidized low density lipoprotein activates peroxisome proliferator-activated receptor-alpha (PPARalpha) and PPARgamma through MAPK-dependent COX-2 expression in macrophages.New drug targets in inflammation: efforts to expand the anti-inflammatory armoury.The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway.COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages.
P2860
Q26778374-764419F4-0FCE-408B-BBE8-61B1D940A25CQ26825075-FBF806C6-37BC-4D11-98C7-9C2AFB436264Q28221357-B46B75C9-75D1-46EE-83E9-68EE666D068AQ34500980-2221F086-5ACC-401D-B03F-6C3A5B2B4BB1Q34570225-A0299F6F-FA9C-4AC3-A285-7751E076580CQ35138964-312DC5FB-D33F-4BE8-98A9-9A3B0C72FE11Q35847266-85872FBA-ED4F-412A-908C-4BB7632A61BEQ36059863-D1570631-C34A-445C-B0B4-2F7767BAC8B6Q36180606-AE0543C0-A984-430D-AFE0-E50E22300CBFQ36220711-2BFD058A-BAB0-43D5-8D6A-5E8774DE596DQ36285935-A70217DF-C070-4ACE-990A-8138A3982552Q36349740-98098E0E-C5F1-4052-939C-CDD0A98FFD38Q36532151-A2493141-38EE-4D67-B4A9-4E6D734AF5B9Q36535634-E10736A4-5FF6-4A5F-A92E-9C8C00E99B18Q36869571-7B30887E-A744-46BD-8D39-3C364144F3AAQ37082097-2358670C-F7EB-4907-B19F-D584D6EE9DD5Q37170511-7D427BD3-DCEC-446F-846D-B13C3E79FC31Q37950866-D109170A-4C4B-4C5A-8D8B-265BA7E3DCC9Q38622970-9895A15C-7F29-4203-AA38-3CF594A3E258Q38805945-6910E176-790B-4132-B41D-92881B14EF47Q40022359-9A74300A-E7F4-4B54-A74A-0EA7EFD5B919Q42123321-0CCA00CB-A35F-42B2-BADB-9C1C52CCB363Q46884698-90272062-B0C5-4005-BE89-9D97E3A4BEAAQ48166277-26D365C0-376E-4E7B-B548-090B71BA6BC7
P2860
Cardiovascular hazard and non-steroidal anti-inflammatory drugs
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Cardiovascular hazard and non-steroidal anti-inflammatory drugs
@ast
Cardiovascular hazard and non-steroidal anti-inflammatory drugs
@en
Cardiovascular hazard and non-steroidal anti-inflammatory drugs
@nl
type
label
Cardiovascular hazard and non-steroidal anti-inflammatory drugs
@ast
Cardiovascular hazard and non-steroidal anti-inflammatory drugs
@en
Cardiovascular hazard and non-steroidal anti-inflammatory drugs
@nl
prefLabel
Cardiovascular hazard and non-steroidal anti-inflammatory drugs
@ast
Cardiovascular hazard and non-steroidal anti-inflammatory drugs
@en
Cardiovascular hazard and non-steroidal anti-inflammatory drugs
@nl
P2093
P1476
Cardiovascular hazard and non-steroidal anti-inflammatory drugs
@en
P2093
Dairong Wang
Dairong Wong
Garret A Fitzgerald
P304
P356
10.1016/J.COPH.2005.02.001
P407
P577
2005-04-01T00:00:00Z